The formula of breviscapine oral disintegrating tablets and its preparation;

Preparation of breviscapine proliposome by fluidized bed coating method;

Changes of high sensitivity C-reactive protein level after Breviscapine injection treatment in acute ischemic stroke patients and its mechanism;

Preparation of breviscapin calcium alginate gel beads;

Effect of breviscapine on the oxygen free radicals in diabetic rats;

Ginaton and Breviscapin rescueing N-Methyl-N-nitrosourea-induced retinal deg eneration in SD rats;

Effect of protein kinase C inhibitor,erigeron breviscapus,on NO/cGMP signaling pathway in hippocampus of hypoxic preconditioning mice;

Experimental study of effect of Erigeron breviscapus on serum TGF-β_1 and renal architecture in diabetic rats;

Effect of Erigeron breviscapus on gelatinase activity and blood-brain barrier permeability during cerebral ischemia-reperfusion in mice;

Preparation and the in vitro release characteristics of scutellarin sustained-release dropping pills;

The study on initial burst release of Scutellarin Proliposome Capsules;

Effects of borneol on the pharmacokinetics of scutellarin in rats;

Study of curative effect of erigeron injection on diabetic foot gangrene and its pathogenesis;

Study of erigeron on brain protection after cerebral ischemia and reperfusion in rats;

Clinical Observation of Astragalus,Erigeron in Treatment of 46 Patients with Idiopathic Nephrotic Syndrome;

Comparison of the in vitro dissolution rate of breviscapine tablets from three different pharmaceutical companies;

AIM: To determination of scutellarin in human plasma by LC-MS method and investigate the pharmacokinetics of breviscapine tablets in Chinese healthy volunteers.